Affinity Asset Advisors LLC grew its position in shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP) by 150.0% during the second quarter, HoldingsChannel reports. The institutional investor owned 50,000 shares of the company’s stock after buying an additional 30,000 shares during the quarter. Affinity Asset Advisors LLC’s holdings in Harpoon Therapeutics were worth $694,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently added to or reduced their stakes in the company. Franklin Resources Inc. bought a new stake in shares of Harpoon Therapeutics in the 1st quarter worth approximately $22,479,000. Sectoral Asset Management Inc bought a new stake in shares of Harpoon Therapeutics in the 1st quarter worth approximately $13,202,000. Nantahala Capital Management LLC bought a new stake in shares of Harpoon Therapeutics in the 1st quarter worth approximately $9,473,000. Orbimed Advisors LLC lifted its holdings in shares of Harpoon Therapeutics by 24.5% in the 1st quarter. Orbimed Advisors LLC now owns 2,285,704 shares of the company’s stock worth $47,817,000 after purchasing an additional 450,000 shares during the last quarter. Finally, UBS Asset Management Americas Inc. acquired a new stake in Harpoon Therapeutics in the 1st quarter valued at approximately $9,260,000. 87.78% of the stock is currently owned by institutional investors.
In related news, CFO Georgia Erbez purchased 10,300 shares of Harpoon Therapeutics stock in a transaction on Wednesday, September 22nd. The stock was bought at an average price of $8.10 per share, with a total value of $83,430.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.40% of the stock is owned by insiders.
Harpoon Therapeutics (NASDAQ:HARP) last announced its quarterly earnings results on Thursday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09). Harpoon Therapeutics had a negative return on equity of 69.42% and a negative net margin of 394.17%. The company had revenue of $5.84 million during the quarter, compared to analyst estimates of $6.61 million. On average, equities research analysts expect that Harpoon Therapeutics, Inc. will post -1.95 EPS for the current year.
Several research firms recently commented on HARP. SVB Leerink lowered their target price on Harpoon Therapeutics from $29.00 to $25.00 and set an “outperform” rating on the stock in a research report on Friday, August 6th. Robert W. Baird reiterated a “buy” rating and set a $35.00 price target on shares of Harpoon Therapeutics in a research report on Sunday, August 15th. Citigroup upgraded Harpoon Therapeutics from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Monday, September 27th. Piper Sandler reiterated an “overweight” rating and set a $30.00 price target (down from $35.00) on shares of Harpoon Therapeutics in a research report on Friday, August 6th. Finally, Zacks Investment Research upgraded Harpoon Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $27.00.
About Harpoon Therapeutics
Harpoon Therapeutics, Inc is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies.
Read More: Understanding Market Liquidity
Want to see what other hedge funds are holding HARP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harpoon Therapeutics, Inc. (NASDAQ:HARP).
Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.